Evidence map›Paper›PMID 41495499›Full record

ArticleAnnals of surgical oncology2026

Outcomes of Second Breast-Conserving Surgery Without Reirradiation for Breast Tumor Recurrence.

Thomas Gaillard, Arnaud Beddok, Yousrah Baadj, Jean-Guillaume Feron, Lauren Darrigues, Léa Pauly, Beatriz Grandal Rejo, Hélène Didelot, Charlotte Van Coppenolle, Fabien Reyal and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Thomas GaillardDepartment Surgical Oncology, Institut Curie, Paris, France.
Arnaud BeddokDepartment of Radiation Oncology, Institut Godinot, Reims, France.
Yousrah BaadjDepartment Surgical Oncology, Institut Curie, Paris, France.
Jean-Guillaume FeronDepartment Surgical Oncology, Institut Curie, Paris, France.
Lauren DarriguesDepartment Surgical Oncology, Institut Curie, Paris, France.
Léa PaulyDepartment Surgical Oncology, Institut Curie, Paris, France.
Beatriz Grandal RejoDepartment Surgical Oncology, Institut Curie, Paris, France.
Hélène DidelotDepartment Surgical Oncology, Institut Curie, Paris, France.
Charlotte Van CoppenolleDepartment Surgical Oncology, Institut Curie, Paris, France.
Fabien ReyalDepartment Surgical Oncology, Institut Curie, Paris, France. fabien.reyal@curie.fr.
Enora LaasDepartment Surgical Oncology, Institut Curie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast-conserving therapy (BCT), combining breast-conserving surgery (BCS) and radiotherapy (RT), is a standard treatment for early stage breast cancer. Despite its effectiveness, patients remain at risk for ipsilateral breast tumor recurrence (IBTR). While mastectomy is traditionally recommended for IBTR, a second BCS with reirradiation (ReRT) has emerged as an alternative. However, there are limited data on outcomes for second BCS without ReRT in low-risk patients. This study aims to assess the outcomes of second BCS without ReRT in patients with low-risk IBTR. PATIENTS AND

methodsThis retrospective cohort study included patients with low-risk IBTR who underwent second BCS without ReRT at the Curie Institute between 2001 and 2023. Eligible patients had hormone receptor-positive, HER2-negative tumors with low histological grade and a size ≤ 2 cm without evidence of lymph node involvement. Data were collected on local recurrence-free survival (LRFS), metastatic recurrence-free survival (MFS), and overall survival (OS).

resultsAmong 154 patients who underwent second BCS without ReRT, 119 had invasive carcinoma and 35 had ductal carcinoma in situ (DCIS). Over a median follow-up of 50 months, 11 patients (7.1%) experienced a second local recurrence, and 6 patients (3.8%) developed metastatic recurrence. Of these 6 metastatic cases, only 2 were associated with synchronous local recurrence. Importantly, no deaths were attributed to breast cancer in this cohort, highlighting the viability of this approach in low-risk patients. Overall survival at 36 months was 98% for invasive carcinoma and 100% for DCIS.

conclusionsSecond BCS without ReRT offers favorable outcomes with low rates of recurrence and metastasis and no breast-cancer-specific mortality in selected low-risk IBTR patients, providing a viable alternative to mastectomy. Further studies with longer follow-up are necessary to confirm these findings and evaluate their applicability in higher-risk populations.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingMastectomy, SegmentalNeoplasm Recurrence, LocalRe-IrradiationAdultAgedFemaleFollow-Up StudiesHumansMiddle AgedPrognosisReoperationRetrospective StudiesSurvival RateDe-escalation therapyIpsilateral breast tumor recurrence (IBTR)Low-risk breast cancerReirradiation (ReRT)Second breast-conserving surgery (BCS)

Identifiers

PMID41495499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.